Digital Pathology Market is estimated to be valued at USD 1,112.8 Mn in 2025 and is expected to reach USD 2,491.0 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 12.2% from 2025 to 2032.
The Digital Pathology Market is growing rapidly due to several important factors that are changing how medical laboratories and hospitals operate today. The rising number of chronic diseases, especially cancer cases, requires faster and more accurate testing methods to help patients get better treatment options. There is a serious shortage of trained pathologists worldwide which automated digital systems are needed to handle the growing workload more effectively.
The new technology improvements in artificial intelligence and medical imaging are making it easier to analyze tissue samples and diagnose diseases much faster. Companies are also launching innovative digital pathology projects that help doctors make better diagnostic decisions and work efficiently in their daily practice. Several government programs are also supporting digital healthcare are helping hospitals and clinics adopt these diagnostics tool and upgrade their existing laboratory infrastructure systems.
|
Current Event |
Description and the Impact |
|
Technological Advancements in AI and Machine Learning |
|
|
Regulatory and Compliance Changes |
|
|
Healthcare Infrastructure and Policy Developments |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
AI is shifting the Digital Pathology Market by making it possible to automate image analysis, use predictive analytics, and detect anomalies. AI-powered tools make it easier to analyze sample tissues, identify patterns, and reach diagnostic conclusions, which cuts down on the need for pathologists to do things by hand and lowers operational costs. Real-time information makes it easier to manage patient care and make clinical decisions. Healthcare facilities can process high-volume pathology cases more efficiently, accurately, and safely by using AI. This is going to enhance diagnostic quality and encourage adoption by large and small healthcare institutions around the world.
For instance, in September 2024, Roche revealed that it was broadening its digital pathology open ecosystem by incorporating over 20 sophisticated artificial intelligence (AI) algorithms from eight new partners. This initiative is deigned to assist pathologists and researchers in cancer research and diagnosis through the application of advanced AI technology.
Based on Product Type, scanner segment contributes the highest share of 43.0% in 2025 of the market owing to the technological upgrades and surge in automation needs. These scanners deliver high image resolution capabilities that capture minute cellular details essential for accurate diagnosis. They also provide faster scanning speeds and greater throughout allowing the laboratories to handle growing case in an efficient manner.
For instance, in December 2025, Leica Biosystems, a Danaher subsidiary and a provider of anatomic pathology solutions took a major step in modernizing diagnostics. At the Digital Pathology and AI Congress in London, the company introduced three new products named Aperio GT 180 DX scanner, Aperio CS5 DX scanner, and Aperio iQC DX software.
Based on Therapeutic Area, the oncology contributes the highest share in 2025 of the market owing to increasing global cancer burden and critical need for accurate tumor diagnosis. Cancer cases are rising globally which is creating unprecedented demand for accurate and timely pathological assessments. Digital pathology allows the oncologists to obtain faster diagnoses which is crucial for initiating cancer therapies.
For instance, in January 2023, Paige teamed up with Microsoft to use artificial intelligence on digital pathology. Their goal was to create new tools and biomarkers that would improve cancer diagnosis and patient care. This partnership aims to bring better diagnostics and more personalized treatment to patients.
Based on Technology, the Immunohistochemistry contribute the highest share in 2025 owing to growing research activities and its important role in disease diagnosis. This technique uses special antibodies to find specific proteins in tissue samples, helping doctors identify cancer types and choose correct treatments. Drug companies are investing heavily in this technology to develop tests that identify which patients will respond well to specific medicines. The technique works for many diseases like cancer, immune disorders, and infections making it widely useful.
Based on End User, Pharmaceutical and Biotechnology Companies segment expected to lead the market with largest share in 2025. It is because these companies are launching new products and conducting extensive drug research. They need to analyze large numbers tissue samples quickly when testing new medicines for safety and effectiveness. Regulatory authorities are also accepting digital pathology results for drug approvals which is encouraging more companies to invest in this technology. Biotech companies are using AI-enabled digital tools to discover new disease markers and create innovative diagnostic tests.
For instance, in April 2025, Roche a biotechnology firm, received the U.S. FDA Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This was the first computational pathology companion diagnostic to receive this recognition. The designation highlighted Roche’s focus on developing innovation that help doctors diagnose cancer more accurately.
To learn more about this report, Download Free Sample
North America has remained the dominant region with a share of 41.7% in 2025 in the market due to the rising approval for new products by health regulators. The region has strong healthcare systems with modern labs and hospitals that are quickly adopting new diagnostic tools and digital technologies. Several top digital pathology companies operate here, thus creating competition that pushes innovation forward and helps the market grow faster. The rising need for remote diagnoses services and online consultation makes hospitals invest more money in digital pathology systems for better efficiency. Also, the support from government through clear rules and standards is encouraging healthcare facilities to switch from traditional methods to digital solutions more confidently.
For instance, in May 2024, Quest Diagnostics, a top provider of diagnostic services, partnered with PathAI, a global leader in AI-powered pathology technology. This multi-year collaboration aims to speed up digital and AI innovations in pathology while enhancing cancer and disease diagnoses through better quality, faster results, and greater efficiency. This deal marks a key advancement for anatomic pathology adoption in the U.S.
The Europe region has emerged as the fastest growing market over the forecast period. The region was among the first regions to adopt digital systems. Digital pathology helps research work together easily by letting pathologist view large image collections and patient data from anywhere in the world. This feature has encouraged many hospitals and research centers across Europe to join forces and use common digital platforms for better results. The growing partnerships between medical facilities in different European countries is increasing the demand for digital pathology tools that allow smooth data sharing and testing.
For instance, in November 2023, Dedalus Group, Europe’s leading provider of anatomic pathology systems teamed up with Ibex Medical Analytics, a frontrunner in AI-driven cancer diagnostics. Together they launched a complete end-to-end AI Digital Pathology Solution for cancer diagnosis. The solutions feature algorithms that boost diagnostic quality and efficiency for expanding customer bases.
The U.S. has been the frontrunner in the digital pathology market with a major share in due to the rising cancer incidence, strong healthcare infrastructure, and increasing use of AI-powered diagnostic tools. The country’s strong healthcare system and heavy investment in research make it a global leader in this field. Pharmaceutical and biotech firms are leveraging digital pathology to speed up clinical trials and biomarker identification in precision medicine.
For instance, in November 2025, U.S.-based Hyland, creator of the Content Innovation Cloud™ partnered with Tribun Health, a digital pathology expert. The integration combines Tribun’s platform with Hyland’s imaging tools to embed AI in diagnostics, helping pathologists deliver faster and more efficient results.
The digital pathology market in Germany is growing quickly due to its excellent healthcare system, focus on innovation and commitment to personalized medicine. The region leads in the adoption of digital diagnostic tools, with hospital and research centers increasingly using digital imaging and AI analysis. Germany laboratories are moving away from traditional microscopes to digital systems allowing for faster diagnoses, better quality checks, and easier collaboration between doctors.
For instance, in November 2024, Mindpeak, GmbH, a pioneer in digital pathology, teamed up with Sagis DX for a landmark study. It tests the new Onychomycosis AI algorithm on PAS-stained slides, aiming to transform detection of fungal nail infections.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1,112.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.2% | 2032 Value Projection: | USD 2,491.0 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Leica Biosystems Nussloch GmbH, Olympus Corporation, F. Hoffmann-La Roche Ltd., Merck KGaA, GE Healthcare, Mikroscan Technologies, Inc., Koninklijke Philips N.V., Sectra AB, Propath UK Limited, Inspirata, Inc., Hamamatsu Photonics, Inc., OracleBio Limited, MD Biosciences, Aiforia, Xybion Digital Inc., Nucleai, Inc |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Digital pathology market grows rapidly because new imaging systems help doctors to diagnose diseases more accurately while making fewer mistakes in healthcare facilities. Artificial intelligence technology analyzes tissue sample automatically and spots patterns quickly which convinces more hospitals and laboratories to purchase this digital equipment. Cloud storage lets pathologist view old patient cases anytime and predict future health trends. Such benefits make these tools very useful for medical businesses.
Advanced scanners equipped with strong computers create clear detailed images that improve diagnosis while reducing costs for hospitals and laboratories using them. Barcode labels stop sample confusion and solve problems with broken glass slides helping pathology labs work faster and save money. New features like label-free imaging and smart learning tools make digital pathology a necessary investment in healthcare companies wanting better results.
For instance, in August 2025, Tempus AI, Inc., a leader in using artificial intelligence to advance precision medicine, completed the purchase of Paige, a specialized digital pathology firm. This move expands Tempus’s data resources, strengthen its expert team, and solidifies its position in digital pathology top-tier technology.
The digital pathology market is experiencing sustained expansion, driven by the increasing adoption of digital imaging systems, artificial intelligence–enabled analysis, and integrated laboratory workflows. Industry data indicate that the market has crossed the billion-dollar threshold in recent years and is expected to multiply in size over the next decade, supported by rising installation of whole-slide imaging scanners and growing software penetration across pathology labs.
North America represents the largest contributor to overall market revenue, supported by advanced healthcare infrastructure, strong regulatory frameworks for digital diagnostics, and early adoption of AI-based pathology solutions. Europe follows closely, benefiting from large-scale digitization initiatives across public healthcare systems. Asia Pacific is emerging as a high-growth region, with expanding hospital networks, rising cancer diagnostic volumes, and increased investment in digital healthcare technologies.
From a component perspective, scanners and imaging hardware account for a significant portion of current deployments, reflecting the foundational need to digitize glass slides. Software platforms, particularly those incorporating machine learning algorithms for image analysis, are witnessing accelerated adoption due to their ability to improve diagnostic efficiency, reproducibility, and workflow automation. Hospitals and diagnostic laboratories remain the primary end users, while pharmaceutical and biotechnology companies increasingly rely on digital pathology for drug development, biomarker discovery, and clinical research.
Definition: The Digital Pathology Market facilitates the digitization and management of pathological specimen data. It provides virtual microscopy solutions that allow pathologists and healthcare institutions to analyze, store, and share digitized slides in in a fast, secure and convenient way. Healthcare providers can use this market to conduct remote diagnoses, collaborate on complex cases with specialists worldwide. They can also integrate AI-powered diagnostics tools and streamline workflow between laboratories and clinicians using computer-based technology for specimen analysis.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
